Ambit Biosciences Inc.'s venture syndicate stepped up for a $30 million Series D-2 round to help support the ongoing Phase II pivotal trial of acute myeloid leukemia (AML) drug AC220 and allow the San Diego-based biotech to avoid the less-than-friendly initial public offering (IPO) market.